Regional disparities in interferon therapy for chronic hepatitis C in Japan: A nationwide retrospective cohort study Infectious Disease epidemiology

BMC Public Health

Volumn 15, Issue 1, 2015, Pages

  Masaki, Naohiko ^a   Yamagiwa, Yoko ^a   Shimbo, Takuro ^b   Murata, Kazumoto ^a   Korenaga, Masaaki ^a   Kanto, Tatsuya ^a   Mizokami, Masashi ^a  

^a National Center for Global Health and Medicine   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Peginterferon ; Ribavirin; Subsidy policy; Treatment outcome; Treatment performance

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RIBAVIRIN;

ADULT; AGED; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; GENOTYPE; HEALTH CARE DISPARITY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; IMMUNOTHERAPY; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEALTHCARE DISPARITIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; JAPAN; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; VIRAL LOAD;

EID: 84934950248     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/s12889-015-1891-2     Document Type: Article

References (23)

1. WHO Fact sheet N°164, Updated April 2014. Hepatitis C. [ http://www.who.int/mediaCenter/factsheets/fs164/en/index.html ] (Accessed June 1, 2015)
2. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433-43.
3. Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-206.
4. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207-17.
5. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-16.
6. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292-303.
7. Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014;61:219-27.
8. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384:403-13.
9. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34-44.
10. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515-23.
11. Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083-91.
12. Japanese Law Translation. Basic Act on Hepatitis Measures. [ http://www.japaneselawtranslation.go.jp/law/detail/?id=1995&vm=04&re=01 ] (Accessed June 1, 2015)
13. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-74.
14. Izumi N, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itoh Y, et al. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:347-68.
15. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-25.
16. Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky JM, Miller V, et al. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology. 2012;56:2398-403.
17. McEwan P, Kim R, Yuan Y. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl Health Econ Health Policy. 2013;11:53-63.
18. O'Connor GT, Quinton HB, Traven ND, Ramunno LD, Dodds TA, Marciniak TA, et al. Geographic variation in the treatment of acute myocardial infarction: the cooperative cardiovascular project. JAMA. 1999;281:627-33.
19. Gentry SE, Massie AB, Cheek SW, Lentine KL, Chow EH, Wickliffe CE, et al. Addressing geographic disparities in liver transplantation through redistricting. Am J Transplant. 2013;13:2052-8.
20. Brantley-Sieders DM, Fan K-H, Deming-Halverson SL, Shyr Y, Cook RS, Local breast cancer spatial patterning. A tool for community health resource allocation to address local disparities in breast cancer mortality. PLoS One. 2012;7, e45238.
21. Jou JH, Sulkowski MS, Noviello S, Long J, Pedicone LD, McHutchison JG, et al. Analysis of site performance in academic-based and community-based centers in the IDEAL Study. J Clin Gastroenterol. 2013;47:e91-5.
22. Thomas DL. Cure of hepatitis C virus infection without interferon alfa: scientific basis and current clinical evidence. Top Antivir Med. 2014;21:152-6.
23. AASLD-IDSA Recommendations for Testing, Managing and Treating Hepatitis C: Initial treatment of HCV infection. [ http://www.hcvguidelines.org/full-report/initial-treatment-hcv-infection ] (Accessed June 1, 2015)